DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c3pbf6/investigation) has announced the addition of the "Investigation Report on China's Montelukast Market, 2010-2019" report to their offering.
Montelukast, developed by Merck, has been widely applied to the treatment of allergic rhinitis and asthma. Montelukast, a selective cysteinyl leukotriene receptor D4 antagonist, selectively combines with leukotriene in the airway and blocks the action of anaphylactic mediator so as to improve respiratory inflammation and keep airway open.
After Singulair's US patent expired on August 3rd 2012, the FDA approved the generic drug applications of over 10 drug makers, among which Teva introduced tablets, chewable tablets and oral granules while Dr. Reddy's introduced tablets and chewable tablets.
According to the author's survey on some sample hospitals in China, the annual sales CAGR of Montelukast in Chinese hospitals exceeded 45% during the period of 2005-2010. With the appearance of some competitive products, the increase of Montelukast in the Chinese market has slowed since 2011, but still remaining an annual growth of over 10%. CAGR sales still reached 25.5% during the period of 2010- 2014.
It has been shown that China has more than 30 million asthma patients and 300-400 million patients suffering from allergic rhinitis. As the environmental pollution worsens in China, the number of patients will keep going up. In China, Montelukast is regarded as one of the most effective antiasthmatic drugs and therefore is estimated to enjoy huge market potential.
Companies Mentioned:
- Sichuan Otsuka Pharmaceutical Co., Ltd.
- Lunan Pharmaceutical Co., Ltd.
- Merck. Co., Inc
- MSD
For more information visit http://www.researchandmarkets.com/research/c3pbf6/investigation
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
